Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 163Sarcoma 48Dermatologic 9Thoracic 7Breast 6Lymphoid 2Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Wilms Tumor 6Ovarian Neoplasms 6Neuroblastoma 5Testicular Neoplasms 4Sarcoma 4Prostatic Neoplasms 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Kidney Neoplasms 4Astrocytoma 4Optic Nerve Glioma 3Oligodendroglioma 3Glioma 3Familial ependymoma 3Choroid Plexus Neoplasms 3Central Nervous System Neoplasms 3Testicular Germ Cell Tumor 2Teratoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Ovarian Germ Cell Cancer 2Neoplasms 2Liver Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1

Interventions

Radiosurgery 9Magnetic Resonance Spectroscopy 6pembrolizumab 4Radiotherapy 4Nivolumab 4Fluorodeoxyglucose F18 4cabozantinib 3Specimen Handling 3Paclitaxel 3Melphalan 3Ipilimumab 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Busulfan 3lenvatinib 2entrectinib 2cediranib 2Thiotepa 2Sunitinib 2Radiation 2Peripheral Blood Stem Cell Transplantation 2Injections 2Ifosfamide 2FAPI-46 2Etoposide 2Carboplatin 2Bone Marrow Transplantation 2Bevacizumab 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2trioctyl phosphine oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Temozolomide × Genitourinary × Clear all
NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Sapience Therapeutics

Phase 1/2 Active not recruiting
125 enrolled
BreastCNSDermatologicGenitourinary

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡